Achieve Life Sciences is a clinical-stage pharmaceutical company engaged in the development and commercialization of cytisinicline for smoking cessation. Co.'s product candidate, Ccytisinicline is a smoking cessation aid that interacts with nicotine receptors in the brain by reducing the severity of nicotine withdrawal symptoms and the reward and satisfaction associated with smoking. Co. has a license and supply agreement with Sopharma, AD (Sopharma) for the development and commercialization of cytisinicline outside of Sopharma's territory, which consists of certain countries in Central and Eastern Europe, Scandinavia, North Africa, the Middle East and Central Asia, as well as Vietnam. We show 10 historical shares outstanding datapoints in our coverage of ACHV's shares outstanding history.
Understanding the changing numbers of ACHV shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like ACHV versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching ACHV by allowing them to research ACHV shares outstanding history
as well as any other stock in our coverage universe. |
Video: Shares Outstanding Importance
